Tunisia’s ANMPS: All Services Become Fee-Based, with a Significant Increase in Tariffs

Tunisia’s ANMPS: All Services Become Fee-Based, with a Significant Increase in Tariffs

By an order dated 13 November 2026, published in the Official Gazette of the Republic of Tunisia (JORT No. 110), the Minister of Health established the list of services provided by the National Agency for Medicines and Health Products (ANMPS) that are subject to fees. As a result, all these services are now chargeable, with fees increasing approximately three- to fourfold compared with the rates previously applied.

What does this order change?

Until now, only certain services provided by the Agency were subject to fees, and the amounts charged were significantly lower. The new order introduces a general fee-based system: every service provided by the ANMPS, from marketing authorisation (MA) applications to inspections, technical opinions, operating authorisations and clinical trial assessments, is now subject to a fee.

The applicable fee varies depending on the nature of the service and the type of product (imported or locally manufactured, reference medicinal product, biological product or generic). Fees must be paid before submitting each application. For imported products, marketing authorisation, transfer and renewal applications must be paid for in convertible currencies.

Why is this important?

The order, issued pursuant to Article 7 of Law No. 2023-2 establishing the Agency, repeals the previous regulatory texts dating from 2011. It provides the ANMPS with its own predictable source of revenue, thereby strengthening its financial autonomy. This will enable the Agency to invest in upgrading its procedures, improving operational efficiency and modernising its services.

Immediate impact on operators

The order does not provide for any transitional period. Companies that have not budgeted for these new fees may face financial constraints and delays in their regulatory activities, including marketing authorisation applications, renewals, variations, inspections and clinical trials.

Furthermore, late renewal applications are subject to a fee twice as high as that applicable to renewals submitted within the prescribed deadlines.